SCHEMBL21158715

SCHEMBL21158715

CCN1CC2CC(C1)N2C(=O)Nc1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 2/20 0.53
MAPT P10636 2/20 0.52
GRIN2B Q13224 3/20 0.51
PAX8 Q06710 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
BLM P54132 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
CCR2 P41597 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
MAOB P27338 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20153135 0.85 MAPT (0.56) ELOVL6MAPTGRIN2BPAX8SMN1; SMN2
SCHEMBL23126197 0.84 MAPT (0.55) ELOVL6MAPTGRIN2BPAX8SMN1; SMN2
SCHEMBL20160526 0.83 ELOVL6 (0.49) ELOVL6MAPTGRIN2BPAX8SMN1; SMN2
SCHEMBL20069826 0.82 KMT2A (0.49) MAPTSMN1; SMN2NPC1RAB9APKM
SCHEMBL20154604 0.82 ELOVL6 (0.53) ELOVL6MAPTGRIN2BPAX8SMN1; SMN2
SCHEMBL20236190 0.76 MAPT (0.80) MAPTSMN1; SMN2BLMTAS1R3TAS1R1
SCHEMBL16178389 0.73 MAPT (0.61) ELOVL6MAPTGRIN2BPAX8SMN1; SMN2
SCHEMBL1574404 0.73 MAPT (0.61) MAPTGRIN2BPAX8SMN1; SMN2BLM
Hydrochloric Acid SCHEMBL16177975 0.71 MAPT (0.62) MAPTGRIN2BPAX8SMN1; SMN2BLM
SCHEMBL1576169 0.71 SMN1; SMN2 (0.70) MAPTGRIN2BPAX8SMN1; SMN2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF ELOVL6 4837/4885MAPT 1769/4885GRIN2B 996/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF ELOVL6 4837/4885MAPT 1769/4885GRIN2B 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.